Quarter-Century PET/Computed Tomography Transformation of Oncology : Hepatobiliary and Pancreatic Cancer - 23/02/24
, Rathan Subramaniam, MD, PhD, MPH, MBA b, c, dRésumé |
[18F] Fluorodeoxyglucose (18F-FDG) PET/CT can improve the staging accuracy and clinical management of patients with hepatobiliary and pancreatic cancers, by detection of unsuspected metastases. 18F-FDG PET/CT metabolic parameters are valuable in predicting treatment response and survival. Metabolic response on 18F-FDG PET/CT can predict preoperative pathologic response to neoadjuvant therapy in patients with pancreatic cancer and determine prognosis. Several novel non-FDG tracers, such as 68Ga prostate-specific membrane antigen (PSMA) and 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT, show promise for imaging hepatobiliary and pancreatic cancers with potential for radioligand therapy.
Le texte complet de cet article est disponible en PDF.Keywords : Hepatocellular carcinoma, Cholangiocarcinoma, Gall bladder carcinoma, Pancreatic carcinoma, FDG PET/CT
Plan
Vol 19 - N° 2
P. 163-175 - avril 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
